Free rides could save sight: new study tests rideshare for diabetic eye care
NCT ID NCT07296952
First seen Jun 27, 2026 ยท Last updated Jun 27, 2026
Summary
This study tests a free rideshare program (PRONTO-EYE) to help diabetic retinopathy patients with Medicaid get to their eye appointments. Researchers will see if offering transportation helps patients attend visits more regularly. The pilot includes 60 English-speaking adults who live within 25 miles of the clinic.
What this could mean
Our plain-language read of the trial. This is informational only โ not medical advice or a prediction.
- Active substance
- rideshare transportation program
- What this could lead to
- If it works, this could show that providing free rides helps patients keep their eye appointments, potentially preventing vision loss from diabetic retinopathy.
- What could go wrong
- This is a small pilot study with only 60 participants, so results may not apply broadly. The program may not improve attendance or could be too costly to scale.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC RETINOPATHY, DR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UI Health
RECRUITINGChicago, Illinois, 60647, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a One-Time gene therapy offer lasting protection for diabetic retinopathy?
- Can tight blood sugar control protect the eyes? a study uses advanced imaging to find out
- Could the speed of blood sugar drop harm the eyes? a study puts it to the test.
- AI eye doctor: could a computer spot Blindness-Causing diseases faster than humans?
- Could a common supplement protect eyes in diabetes?
- Eye scan showdown: faricimab vs ranibizumab in diabetic retinopathy